Huntington shopping center to begin $31 2M in renovations ahead of ShopRite s arrival newsday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newsday.com Daily Mail and Mail on Sunday newspapers.
Even post-vaccine, CT shoppers are buying groceries online. Here s what to know before you buy.
FacebookTwitterEmail
1of3
An Amazon delivery person places a grocery order inside a customer s garage. The e-commerce giant has expanded its Key by Amazon In-Garage Grocery Delivery service to more than 5,000 communities nationwide, include select Connecticut sip codes in the Hartford and New Haven areas.Contributed photoShow MoreShow Less
2of3
Peapod trucks get loaded up with grocieries from Super Stop and Shop in Norwalk, Conn.Erik Trautmann / Hearst Connecticut MediaShow MoreShow Less
3of3
As Connecticut and the rest of the country emerges from the pandemic, nobody knows for sure if typical grocery shopping habits roaming up and down the aisles, looking for cereal and toilet paper, for example will return to normal.
Share this article
SAN DIEGO, March 3, 2021 /PRNewswire/
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer, castrate-resistant prostate cancer and leukemias, today announced that the Company will present at the upcoming H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021. The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7 a.m. ET on Tuesday, March 9, 2021. The Company will also participate in one-on-one meetings with investors during the conference.
About Cardiff Oncology, Inc.
Cardiff Oncology Announces Fourth Quarter and Full Year 2020 Results and Recent Highlights
News provided by
Share this article
SAN DIEGO, Feb. 25, 2021 /PRNewswire/
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer, castrate-resistant prostate cancer and leukemias, today announced recent company highlights and financial results for the fourth quarter and full year ended December 31, 2020. Over the last several months we achieved key clinical milestones, which provided the momentum for our successful raise of over $100 million. Together, these events have enabled us to accelerate the execution of our clinical programs and expand our pipeline to other relevant cancer indications, said Dr. Mark Erlander, chief executive officer of Cardiff Oncology. Data from our lead KRAS-mutated metastatic color